BIAF
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.51
−5.90%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.67
From 52W high−95.06%
Volume66598.00
Market cap$4.50M
P/E (TTM)—
P/S (TTM)0.8x
Div yield—
Key dataOct 19, 2026
Open
$3.67
From 52W high
−95.06%
Volume
66598.00
Market cap
$4.50M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
34.9
MomentumView details →
1D Return
−5.90%
YTD Return
−79.83%
SummaryUpdated Jun 1, 2026
bioAffinity Technologies, Inc. (NASDAQ:BIAF) is a biotechnology company founded in 2014 and based in San Antonio, Texas. The company went public in September 2022 and specializes in developing non-invasive diagnostic tests and targeted cancer therapeutics. bioAffinity Technologies operates in the medical diagnostics and research sector, focusing primarily on early detection of lung cancer through innovative testing methods and researching targeted therapies to treat cancer at the cellular level.
Similar companies
Latest newsMore news →
bioAffinity Technologies appointed WallachBeth Capital LLC as exclusive placement agent on a best-efforts basis for the offering.10d agobioAffinity Technologies entered into a securities purchase agreement to sell 116,545 common shares and pre-funded warrants for 536,836 shares, and issued warrants for 980,072 shares in a private placement expected to generate approximately $4 million in gross proceeds.10d agobioAffinity Technologies, Inc. announced that it received notice of allowance for a Japanese patent covering its noninvasive CyPath Lung diagnostic test and AI-built algorithm.12d ago